Bass AIA Challenge To Celgene Cancer Drug Patent Rejected
The Patent Trial and Appeal Board has rejected a request by hedge fund manager Kyle Bass to review a Celgene Corp. patent on the compound for the cancer drug Revlimid, finding...To view the full article, register now.
Already a subscriber? Click here to view full article